Systematic Reviews
Copyright ©The Author(s) 2022.
World J Gastroenterol. Sep 7, 2022; 28(33): 4890-4908
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4890
Table 3 Characteristics of included studies
Ref.
Study design
Sample size (E/C)
Gender (E/C) and age (yr)
Duration
Interventions
Period
Outcome measure
Balance report of baseline
Control group
Experimental group
Yun[27], 2014RCT48 (24/24)(13/11) (10/14); (34.96 ± 11. 39)/(34.08 ± 12.82)Not mentionedRabeprazole enteric-coated capsuleRabeprazole enteric-coated capsule + SLBZD4 wkEffective rateP > 0.05
Chen et al[28], 2014RCT79 (40/39)(24/16) (23/16); (42.6 ± 13.1)/43.5 ± 13.46-17 mo/6-19 moTriple therapy (clarithromycin sustained-release tablets + rabeprazole sodium capsule + metronidazole tablets)Triple therapy + SLBZD4 wkEffective rateP > 0.05
Chen et al[29], 2018RCT60 (30/30)(14/16) (15/15); (55.45 ± 6.55)/(55.46 ± 6.44)3-12 moQuadruple therapy (rabeprazole sodium capsule + amoxicillin + clarithromycin sustained-release tablets + biskalcitrate)Quadruple therapy + SLBZD8 wkEffective rate; H. Pylori eradication; adverse eventP > 0.05
Du[30], 2017RCT48 (26/22)(14/12) (12/10); (40.7 ± 6.1)/(41.2 ± 6.6)7 mo-9 years/6 mo-8 yearsQuadruple therapy (amoxicillin clavulanic potassium chewable tablets + metronidazole + omeprazole + compound bismuth aluminate capsule)SLBZD5 wkEffective rateP > 0.05
Gu[31], 2017RCT98 (49/49)Not mentioned; 19-58Not mentionedTriple therapy (omeprazole + clarithromycin + amoxicillin)Triple therapy + SLBZD4 wkEffective rate; H. Pylori eradication rate; adverse eventP > 0.05
Li et al[32], 2020RCT66 (33/33)(19/14) (18/15); (58.54 ± 4.65)/(58.62 ± 4.57)4-17 years/4-18 yearsTriple therapy (mosapride tablet + polyzyme tablets + lansoprazole tablets)Triple therapy + SLBZD12 wkEffective rateP > 0.05
Tang[33], 2014RCT60 (30/30)(16/14) (17/13); (22-46)/(23-52)Not mentionedOmeprazole enteric-coated capsulesOmeprazole Enteric-coated Capsules + SLBZD8 wkEffective rateP > 0.05
Xia[34], 2015RCT300 (150/150)Not mentioned; 18-85Not mentionedOmeprazole enteric-coated capsulesSLBZD8 wkEffective rate; recurrence rate; adverse eventP > 0.05
Xu et al[35], 2018RCT60 (30/30)(17/13) (16/14); (55.6 ± 16.4)/(56.8 ± 14.9)4-20 years/4-19 yearsTriple therapy (mosapride tablet + polyzyme tablets + lansoprazole tablets)Triple therapy+SLBZD12 wkEffective rateP > 0.05
Zhang et al[36], 2020RCT68 (34/34)(15/19) (17/17); (44.8 ± 5.0)/(45.2 ± 5.4)1-12 years/2-14 yearsCombination therapy (omeprazole + compound bismuth aluminate granules)Combination therapy + SLBZD8 wkEffective rate; adverse eventsP > 0.05
Zhao and Lin[37], 2010RCT80 (40/40)(37/3) (38/2); (46.2 ± 6.7)/(44.2 ± 5.7)2-7 years/2-8 yearsNo alcohol, famotidineNo alcohol, famotidine + SLBZD4 wkEffective rate;P > 0.05
Zheng[38], 2014RCT92 (46/46)(28/18) (30/16); ( 34 ± 5.34)/( 33 ± 5.76)5 mo-6 years/7 mo-6 yearsTriple therapy (amoxicillin dispersion tablet + omeprazole enteric-coated capsules + clarithromycin tablet)SLBZD4 wkEffective rate; adverse events; recurrence rateP > 0.05
Zhuang et al[39], 2019RCT106 (53/53)(65/41); (46.20 ± 8.75)1-11 yearsTriple therapy (omeprazole enteric-coated tablets + clarithromycin dispersible tablets+amoxil capsule)Triple therapy + SLBZD4 wkEffective rate; H. Pylori’s negative conversion rateP > 0.05
Zou[40], 2015RCT170 (85/85)(86/84); (40.9 ± 11.1)Not mentionedTriple therapy (amoxicillin + clarithromycin + omeprazole)Triple therapy + SLBZD8 wkEffective rate; H. Pylori’s negative conversion rate; recurrence rateP > 0.05